Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
At week 72, tirzepatide was associated with 18.5% reduction in BMI, compared with 0.5% increase in BMI with placebo, demonstrating superiority over placebo (estimated treatment difference, −19.0 [95% CI, −23.9 to −14.1] percentage points; P < .001).
Appeared: Tuesday, November 17. JAMA. Peer-reviewed journal.